Case reports in dermatology · 2025
Emergence of Vitiligo during Treatment with Risankizumab-Rzaa for Plaque Psoriasis: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thomas Kevin V, Tran Jennifer M, Cotter Lisa M
Аннотация
INTRODUCTION: Risankizumab-rzaa (Skyrizi) is a humanized monoclonal antibody (IgG1) approved for the treatment of severe plaque psoriasis. It selectively blocks the p19 subunit of the IL-23 pathway, leading to reduced keratinocyte proliferation reducing the inflammatory response.
CASE PRESENTATION: We present a case of de novo vitiligo in a patient being treated with risankizumab-rzaa (Skyrizi) for plaque psoriasis. Our patient had extensive plaque psoriasis affecting his trunk, upper extremities, and scalp, encompassing 30% of his total body surface area. He was treated with risankizumab-rzaa, an IL-23 inhibitor, with significant improvement of his psoriasis and residual hyperpigmented, post-inflammatory patches. In addition, he developed new-onset vitiligo, for which he declined treatment and was continued on risankizumab-rzaa. On subsequent follow-up over a year later, there were extensive areas of vitiligo now with a trichrome pattern suggestive of active vitiligo.
CONCLUSION: To our knowledge, no cases of de novo vitiligo associated with risankizumab-rzaa have been reported in the literature, and our patient may represent the first reported case. The role of IL-23 remains unclear, and our case represents the importance of further research to better elucidate IL-23's role in vitiligo.
CASE PRESENTATION: We present a case of de novo vitiligo in a patient being treated with risankizumab-rzaa (Skyrizi) for plaque psoriasis. Our patient had extensive plaque psoriasis affecting his trunk, upper extremities, and scalp, encompassing 30% of his total body surface area. He was treated with risankizumab-rzaa, an IL-23 inhibitor, with significant improvement of his psoriasis and residual hyperpigmented, post-inflammatory patches. In addition, he developed new-onset vitiligo, for which he declined treatment and was continued on risankizumab-rzaa. On subsequent follow-up over a year later, there were extensive areas of vitiligo now with a trichrome pattern suggestive of active vitiligo.
CONCLUSION: To our knowledge, no cases of de novo vitiligo associated with risankizumab-rzaa have been reported in the literature, and our patient may represent the first reported case. The role of IL-23 remains unclear, and our case represents the importance of further research to better elucidate IL-23's role in vitiligo.